source
- Advanced analytics enable up to 12% cut in control animal use while keeping study rigorThe control group is a cornerstone of nonclinical safety studies, providing the baseline needed to separate a drug’s effects from normal biological variation. Researchers are now applying virtual…
- AbbVie halts development of livmoniplimab after deeming benefit limitedAbbVie announced it is discontinuing the phase 2 development of its monoclonal antibody livmoniplimab (ABBV-151) after concluding the drug is unlikely to outperform existing therapies. The drug wa…